- Home
- CELU vs ALGS Comparison
CELU vs ALGS Comparison
Compare CELU & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- ALGS
- Stock Information
- Founded
- CELU 2016
- ALGS 2018
- Country
- CELU United States
- ALGS United States
- Employees
- CELU N/A
- ALGS N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- ALGS Health Care
- Exchange
- CELU Nasdaq
- ALGS Nasdaq
- Market Cap
- CELU 42.2M
- ALGS 38.8M
- IPO Year
- CELU N/A
- ALGS 2020
- Fundamental
- Price
- CELU $1.37
- ALGS $5.43
- Analyst Decision
- CELU
- ALGS Strong Buy
- Analyst Count
- CELU 0
- ALGS 1
- Target Price
- CELU N/A
- ALGS $70.00
- AVG Volume (30 Days)
- CELU 97.9K
- ALGS 140.3K
- Earning Date
- CELU 12-06-2024
- ALGS 03-10-2025
- Dividend Yield
- CELU N/A
- ALGS N/A
- EPS Growth
- CELU N/A
- ALGS N/A
- EPS
- CELU N/A
- ALGS N/A
- Revenue
- CELU $48,200,000.00
- ALGS $3,945,000.00
- Revenue This Year
- CELU N/A
- ALGS $580.86
- Revenue Next Year
- CELU $233.89
- ALGS N/A
- P/E Ratio
- CELU N/A
- ALGS N/A
- Revenue Growth
- CELU 225.94
- ALGS N/A
- 52 Week Low
- CELU $1.00
- ALGS $6.42
- 52 Week High
- CELU $5.69
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- CELU 40.70
- ALGS 22.66
- Support Level
- CELU $1.64
- ALGS $10.45
- Resistance Level
- CELU $2.40
- ALGS $9.76
- Average True Range (ATR)
- CELU 0.20
- ALGS 1.05
- MACD
- CELU -0.02
- ALGS -0.01
- Stochastic Oscillator
- CELU 0.00
- ALGS 1.04
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.